From the Research
Farxiga (dapagliflozin) can be given to patients with elevated Liver Function Tests (LFTs), but with careful monitoring, especially in those with severe hepatic impairment. The most recent and highest quality study, 1, suggests that dapagliflozin effectively improves liver function parameters and metabolic outcomes among patients with nonalcoholic fatty liver disease (NAFLD). Key points to consider when prescribing Farxiga to patients with elevated LFTs include:
- Monitoring liver function tests regularly during treatment
- Investigating and addressing the underlying cause of elevated LFTs
- Considering alternative diabetes medications if the elevation is severe or if there are signs of liver failure
- Being aware of the potential for dapagliflozin to increase total cholesterol levels
- Starting with a lower dose of 5 mg in patients with severe hepatic impairment It is essential to weigh the benefits and risks of using Farxiga in patients with elevated LFTs, considering the potential for improved glycemic control and metabolic outcomes, as well as the potential for adverse effects. The study 1 provides the most recent and relevant evidence, showing that dapagliflozin can reduce levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), and improve metabolic outcomes such as body weight, body mass index (BMI), low-density lipoprotein cholesterol (LDL-C), and triglycerides. However, it is crucial to prioritize the patient's safety and adjust the treatment plan accordingly, taking into account the severity of the liver dysfunction and the potential for drug interactions. In clinical practice, it is recommended to follow the guidelines and consult with a specialist if necessary, to ensure the best possible outcome for the patient.